Serum human chorionic gonadotropin regression pattern in persistent trophoblastic disease during chemotherapy.

Simple item page
dc.contributor.authorLertkhachonsuk, Ren_US
dc.contributor.authorLimpongsanurak, Sen_US
dc.date.accessioned2009-05-27T21:46:59Z
dc.date.available2009-05-27T21:46:59Z
dc.date.issued2001-06-01en_US
dc.descriptionChotmaihet Thangphaet.en_US
dc.description.abstractThe objective of this study was to identify the regression pattern of serum beta-hCG in persistent trophoblastic disease patients after initiating chemotherapy. Eighty-nine women who were diagnosed as persistent trophoblastic disease in King Chulalongkorn Memorial Hospital between January 1985 and December 1998, and received single agent chemotherapy were included. The incidence was 20.2 per cent of total gestational trophoblastic disease patients. Seventy-two (80.9%) from 89 patients were recruited in our study. Sixty-four (88.9%) patients responded to first-line chemotherapy and 8 patients (11.1%) resisted. Suction curettage was done as initial treatment in 61 (84.7%) cases. Most of them (95.8%) received actinomycin-D as first line treatment. Total courses of chemotherapy averaged 4 courses, but increased to 8.5 courses in the resistant group. Mean time of serum beta-hCG to remission was 16.7 and 21.5 weeks in the chemo-sensitive and chemo-resistant group, respectively. Average time to start chemotherapy was in the tenth week, and in the resistant group it was started in the sixth week. Chemotherapy regimen was changed in the fifteenth week. Initial serum beta-hCG levels were not significantly different between the two groups. The reduction rates of beta-hCG were significantly different from the third to the seventh week in the chemo-sensitive and chemo-resistant groups, which was during the second and third course of chemotherapy (P<0.05). In conclusion, by using the reduction rate, the regression pattern of serum beta-hCG level in persistent trophoblastic disease patients was significantly different between the chemosensitive and chemoresistant group from the third to the seventh week after starting chemotherapy.en_US
dc.description.affiliationDepartment of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.en_US
dc.identifier.citationLertkhachonsuk R, Limpongsanurak S. Serum human chorionic gonadotropin regression pattern in persistent trophoblastic disease during chemotherapy. Journal of the Medical Association of Thailand. 2001 Jun; 84 Suppl 1(): S352-9en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/45394
dc.language.isoengen_US
dc.source.urihttps://www.mat.or.th/journal/all.phpen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshChorionic Gonadotropin --analysisen_US
dc.subject.meshCohort Studiesen_US
dc.subject.meshDactinomycin --administration & dosageen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshDrug Resistanceen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshHydatidiform Mole --diagnosisen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPredictive Value of Testsen_US
dc.subject.meshPregnancyen_US
dc.subject.meshProbabilityen_US
dc.subject.meshPrognosisen_US
dc.subject.meshSensitivity and Specificityen_US
dc.subject.meshSeverity of Illness Indexen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshTumor Markers, Biological --blooden_US
dc.subject.meshUterine Neoplasms --diagnosisen_US
dc.titleSerum human chorionic gonadotropin regression pattern in persistent trophoblastic disease during chemotherapy.en_US
dc.typeComparative Studyen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Medical Association of Thailand